Clinical Trial

Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 23, 2024 (before its estimated December 23, 2025 completion). Its status may not reflect the trial's current state.
Summary
Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-17.
Trial Details
NCT Number NCT06006819
Lead Sponsor Cheng-Hsin General Hospital
Conditions Chronic Kidney Diseases, Acute Heart Failure, Biomarker
Enrollment 155 participants
Start Date 2023-01-01
Primary Completion 2025-12-23 (estimated)
Study Completion 2025-12-23 (estimated)
Updated on ClinicalTrials.gov 2024-08-23